Close Menu

X-ray

In Print: Apr 14, 2009

Premium

Microarray-Related Papers of Note Published in March 2009

The deal calls for Proteros to use its crystallography platform to decipher the X-ray structure of Axikin's protein, develop assays, identify active fragments, and develop the selected fragments into novel lead drug candidates.

Though the firm's revenues were down year over year for the quarter, its full-year 2008 revenues increased 7 percent. Investors also sent Bruker's shares up in early trade, as the firm handily beat analysts' consensus estimate for EPS.

Industry Briefs: Feb 26, 2009

Premium

Mosaiques, Bruker, Kinaxo, Xencor, CSL, Hybrigenics, Adlyfe, Wyeth

Receipts for the firm’s life sciences division, which houses its LC-MS tools, slid 1 percent but company officials said that LC-MS and mass-spec sales experienced double-digit growth.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.